UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1369-4
Program Prior Authorization/Notification
Medication Stromectol® (ivermectin) oral dosage form
P&T Approval Date 9/2021, 12/2022, 1/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Ivermectin (oral dosage form) is indicated for the treatment of parasitic infections including
strongyloidiasis and onchocerciasis. Ivermectin may also be used for other compendia
supported parasitic infections including but not limited to scabies, hookworm disease, and
ascariasis. Most infections are treated with a single weight-based dose. The U.S. Food and
Drug Administration (FDA) has determined that currently available clinical trial data do not
demonstrate that ivermectin is effective against COVID-19 in humans1.
2. Coverage Criteriaa:
A. Stromectol (ivermectin) will be approved based on the following criterion:
1. Diagnosis of one of the following:
a. Onchocerciasis due to nematode parasite.
b. Pediculosis
c. Strongyloidiasis
d. Ascariasis
e. Scabies (including crusted scabies)
f. Cutaneous larva migrans (hook worm disease)
g. Enterobiasis
h. Filariasis
i. Trichuriasis
Authorization will be issued for 1 month
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits, Medical Necessity and/or Step Therapy may be in place.
© 2025 UnitedHealthcare Services, Inc.
1
4. References:
1. U.S. Food and Drug Administration. Ivermectin and COVID-19. Updated April 5, 2024.
Accessed February 2, 2025.
2. Ivermectin [package insert]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC.; March
2022.
3. Clinical Pharmacology [database online]. Ivermectin. Tampa, FL: Gold Standard, Inc.;
2022. Updated February 10, 2025.
Program Prior Authorization/Notification - Stromectol (ivermectin)
Change Control
9/2021 New program.
12/2022 Updated references, added state mandate footnote, revised language in
background to align with updated NIH reference.
1/2024 Annual review. Updated references.
3/2025 Annual review. Updated references and background with FDA
reference.
© 2025 UnitedHealthcare Services, Inc.
2